Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Respirent's Fluticasone/Salmeterol vs Advair Diskus
NCT06025214Phase 1Unknown
- Sponsor
- Respirent Pharmaceuticals Co. Ltd.
- Start
- Aug 2023
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone propionate and salmeterol in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Respirent Pharmaceuticals Co. Ltd. Primary endpoints: Maximum Observed Plasma Concentration for Fluticasone Propionate, Maximum Observed Plasma Concentration for Salmeterol and 2 more. Status: unknown.
02
Drugs
fluticasone propionatesalmeterol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06025214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06025214.